DNA Repair Genes and Chronic Myeloid Leukemia: XPD (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (1394) Gene Polymorphisms Polymorphisms of DNA Repair Genes in CML

Main Article Content

Istemi SERIN


CML, DNA Repair, XRCC 4, XRCC 1, XPD, Polymorphism, Prognosis


No Abstract required


Download data is not yet available.

Abstract 691
PDF Downloads 189
HTML Downloads 122


Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003 May 20;138(10):819-30. DOI: 10.7326/0003-4819-138-10-200305200-00010
Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in “good- risk” chronic granulocytic leukemia. Blood 1984;63:789-799.
Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-858. DOI: 10.1093/jnci/90.11.850
Thapa B, Rogers HJ. Cancer, Myeloproliferative Neoplasms. [Updated 2019 Nov 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531464/
Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003 Sep;55(3):401-23. Epub 2003 Jul 17. DOI: 10.1124/pr.55.3.4
Hochhaus A, Baccarani M, Silver RT et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-984. DOI: 10.1038/s41375-020-0776-2.
Das-Gupta EP, Seedhouse CH, Russell NH. DNA repair mechanisms and acute myeloblastic leukemia. Hematol Oncol. 2000 Sep;18(3):99-110. DOI: 10.1002/1099-1069(200009)18:3<99::aid-hon662>3.0.co;2-z.
Taylor EM, Broughton BC, Botta E et al. Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8658-63. DOI: 10.1073/pnas.94.16.8658.
Artac M, Bozcuk H, Pehlivan S et al (2010). The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. J. Cancer Res. Clin. Oncol. 136: 803-809.
Shen M, Hung RJ, Brennan P et al. (2003). Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in Northern Italy. Cancer Epidemiol. Biomarkers Prev. 12: 1234-1240.
Sreeja L, Syamala VS, Syamala V et al. (2008). Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J. Cancer Res. Clin. Oncol. 134: 645-652.
Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA (2001). DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol. Biomarkers Prev. 10: 125-131.
Yang ZH, Du B, Wei YS et al. (2007). Genetic polymorphisms of the DNA repair gene and risk of nasopharyngeal carcinoma. DNA Cell Biol. 26: 491-496.
Ruzzo A, Canestrari E, Maltese P et al. (2007). Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. Clin. Chem. Lab. Med. 45: 822-828.
Chacko P, Rajan B, Joseph T, Mathew BS, Pillai MR. Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer. Breast Cancer Res Treat. 2005;89(1):15-21. DOI:10.1007/s10549-004-1004-x
Lu J, Wang XZ, Zhang TQ et al. Prognostic significance of XRCC4 expression in hepatocellular carcinoma. Oncotarget. 2017 Sep 28;8(50):87955-87970. DOI: 10.18632/oncotarget.21360.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215. doi: 10.1093/nar/16.3.1215.
Salimizand H, Amini S, Abdi M, Ghaderi B, Azadi NA. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumour Biol. 2016 Jan;37(1):791-8. DOI: 10.1007/s13277-015-3874-4.
Wang F, Zhao Q, He HR et al. The association between XRCC1 Arg399Gln polymorphism and risk of leukemia in different populations: a meta-analysis of case-control studies. Onco Targets Ther. 2015 Nov 6;8:3277-87. DOI: 10.2147/OTT.S92752.
Deligezer U, Akisik EE, Dalay N. Lack of association of XRCC1 codon 399Gln polymorphism with chronic myelogenous leukemia. Anticancer Res. 2007 Jul-Aug;27(4B):2453-6.
Özcan, A, Pehlivan, M, Tomatir, A et al. (2011). Polymorphisms of the DNA repair gene XPD (751) and XRCC1 (399) correlates with risk of hematological malignancies in Turkish population. African Journal of Biotechnology. 10. 8860-8870. 10.5897/AJB10.1839.
Annamaneni S, Gorre M, Kagita S et al. Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India. Hematology. 2013 May;18(3):163-8. DOI: 10.1179/1607845412Y.0000000040.
Joshi D, Korgaonkar S, Shanmukhaiah C, Vundinti BR. Association of XPD (Lys751Gln) and XRCC1 (Arg280His) gene polymorphisms in myelodysplastic syndrome. Ann Hematol. 2016 Jan;95(1):79-85. DOI: 10.1007/s00277-015-2528-3.